The DOI matches its Crossref record; 70 of the 76 references it cites were found in a registry or an index.
mTOR Signaling Inhibition Modulates Macrophage/Microglia-Mediated Neuroinflammation and Secondary Injury via Regulatory T Cells after Focal Ischemia
Open accessAbstract
Signaling by the mammalian target of rapamycin (mTOR) plays an important role in the modulation of both innate and adaptive immune responses. However, the role and underlying mechanism of mTOR signaling in poststroke neuroinflammation are largely unexplored. In this study, we injected rapamycin, a mTOR inhibitor, by the intracerebroventricular route 6 h after focal ischemic stroke in rats. We found that rapamycin significantly reduced lesion volume and improved behavioral deficits. Notably, infiltration of γδ T cells and granulocytes, which are detrimental to the ischemic brain, was profoundly reduced after rapamycin treatment, as was the production of proinflammatory cytokines and chemokines by macrophages and microglia. Rapamycin treatment prevented brain macrophage polarization toward the M1 type. In addition, we also found that rapamycin significantly enhanced anti-inflammation activity of regulatory T cells (Tregs), which decreased production of proinflammatory cytokines and chemokines by macrophages and microglia. Depletion of Tregs partially elevated macrophage/microglia-induced neuroinflammation after stroke. Our data suggest that rapamycin can attenuate secondary injury and motor deficits after focal ischemia by enhancing the anti-inflammation activity of Tregs to restrain poststroke neuroinflammation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“which were previously involved in restricting amyloidosis56, microglial response to pathogens57, and pro-inflammatory microglia58”
From Transcriptional signature in microglia associated with Aβ plaque phagocytosis (2021) · cites this paper as [58]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Protective and pathogenic functions of macrophage subsets
Murray, P. J., & Wynn, T. A. (2011) · Nature Reviews Immunology · doi:10.1038/nri3073 · Cited by 5,269 · cited 2×
“According to published M1 and M2 phenotypes (32, 33), we”
BackgroundHeart Disease and Stroke Statistics—2014 Update
Go, A. S., Mozaffarian, D., Roger, V. L., Benjamin, E. J., Berry, J. D., Blaha, M. J., Dai, S., Ford, E. S., Fox, C. S., Franco, S., et al. (2013) · Circulation · doi:10.1161/01.cir.0000441139.02102.80 · Cited by 5,264
Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm
Biswas, S. K., & Mantovani, A. (2010) · Nature Immunology · doi:10.1038/ni.1937 · Cited by 3,840 · cited 1×
“According to published M1 and M2 phenotypes (32, 33), we”
BackgroundThe immunology of stroke: from mechanisms to translation
Iadecola, C., & Anrather, J. (2011) · Nature Medicine · doi:10.1038/nm.2399 · Cited by 2,596 · cited 2×
“Both damaged/stressed neurons and reactive astrocytes quickly initiate postischemic inflammation, through producing proinflammatory mediators and educating microglia (42, 67, 68).”
BackgroundLaplante, M., & Sabatini, D. M. (2009) · Journal of Cell Science · doi:10.1242/jcs.051011 · Cited by 2,284 · cited 1×
“under physiological and pathological conditions (7, 8).”
The inhibitory cytokine IL-35 contributes to regulatory T-cell function
Collison, L., Workman, C., Kuo, T. T., Boyd, K., Wang, Y., Vignali, K. M., Cross, R., Sehy, D., Blumberg, R., & Vignali, D. (2007) · Nature · doi:10.1038/nature06306 · Cited by 2,152 · cited 9×
“Three days and 5 d after the initial Ab injection, .50 and 60% of CD4+Foxp3+ Tregs in the blood were depleted, respectively (Fig.”
BackgroundInfluentialA Semiautomated Method for Measuring Brain Infarct Volume
Swanson, R. A., Morton, M. T., Tsao-Wu, G., Savalos, R. A., Davidson, C. L., & Sharp, F. R. (1990) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.1990.47 · Cited by 1,629 · cited 1×
“Lesion area was measured by a blinded observer, as described previously (14).”
MethodHu, X., Li, P., Guo, Y., Wang, H., Leak, R. K., Chen, S., Gao, Y., & Chen, J. (2012) · Stroke · doi:10.1161/strokeaha.112.659656 · Cited by 1,573 · cited 1×
“Previous studies have documented the proinflammatory (M1) and anti-inflammatory (M2) macrophages in the postischemic brains (65, 66).”
Inflammatory mechanisms in ischemic stroke: role of inflammatory cells
Jin, R., Yang, G., & Li, G. (2010) · Journal of Leukocyte Biology · doi:10.1189/jlb.1109766 · Cited by 1,521 · cited 2×
“Poststroke neuroinflammation plays critical roles in the pathophysiology of ischemic stroke, which is characterized by peripheral leukocyte influx into the cerebral parenchyma, activation of endogenous microglia, and release of proinflammatory mediators (5, 39).”
BackgroundThornton, A. M., Korty, P. E., Tran, D. Q., Wohlfert, E. A., Murray, P. E., Belkaid, Y., & Shevach, E. M. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0904028 · Cited by 1,382 · cited 1×
“Splenic Tregs contain mainly natural Tregs (38).”
Research works printed but not linked: 2
- Shichita, 2009, Pivotal role of cerebral interleukin-17-producing gammadeltaT cells in the delayed phase of ischemic brain injury, Nat. Med., 15, 946, 10.1038/nm.1999 · DOI · Paper page
- Lakhan, 2009, Inflammatory mechanisms in ischemic stroke: therapeutic approaches, J. Transl. Med., 7, 97, 10.1186/1479-5876-7-97 · DOI
Cited by
Sorted by citations
Jurcău, A., & Simion, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms23010014 · Cited by 532
“Treg depletion led to increased infarct sizes in three studies [288–290], and one study found a reduced infarct size in Treg-deficient mice [111], while other studies could not detect any influence on infarct size [111,291].”
ResultMicroglia: Agents of the CNS Pro-Inflammatory Response
Rodríguez-Gómez, J. A., Kavanagh, E., Engskog-Vlachos, P., Engskog, M. K. R., Herrera, A. J., Espinosa-Oliva, A. M., Joseph, B., Hajji, N., Venero, J. L., & Burguillos, M. A. (2020) · Cells · doi:10.3390/cells9071717 · Cited by 365
Transcriptional signature in microglia associated with Aβ plaque phagocytosis
Grubman, A., Choo, X. Y., Chew, G., Ouyang, J. F., Sun, G., Croft, N. P., Rossello, F. J., Simmons, R., Buckberry, S., Landin, D. V., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23111-1 · Cited by 357
Immune cell regulation of glia during CNS injury and disease
Greenhalgh, A. D., David, S., & Bennett, F. C. (2020) · Nature reviews. Neuroscience · doi:10.1038/s41583-020-0263-9 · Cited by 411
Modulators of microglia activation and polarization in ischemic stroke
Jiang, C., Wu, W., Deng, Y.-H., & Ge, J.-W. (2020) · Molecular Medicine Reports · doi:10.3892/mmr.2020.11003 · Cited by 355
“…was observed to recruit cd8 + γδ T cells to the ischemic brain, which was identified to be the primary factor aggravating brain infarction (32,33). in fact, besides ischemic stroke, M1 microglia activation occurs in multiple other neurological diseases; for example, in an RD1 mouse model…”
Xu, X., Gao, W., Li, L., Hao, J.-H., Yang, B., Wang, T., Li, L., Bai, X.-S., Li, F., Ren, H., et al. (2021) · Journal of Neuroinflammation · doi:10.1186/s12974-021-02174-3 · Cited by 253
Self-citationThe Involvement and Therapy Target of Immune Cells After Ischemic Stroke
Jian, Z., Liu, R., Zhu, X., Smerin, D., Zhong, Y., Gu, L., Fang, W., & Xiong, X. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02167 · Cited by 236
“Inhibition of mTORC1 pathway by everolimus reduced microglia polarizing to pro-inflammatory M1 phenotype, alleviated secondary injury and improved motor functions, which directly acts of microglia and macrophages (146, 147) (Table 3).”
BackgroundWang, Y., Tian, M., Tan, J., Pei, X., Lu, C., Xin, Y., Deng, S., Zhao, F., Gao, Y., & Gong, Y. (2022) · Journal of Neuroinflammation · doi:10.1186/s12974-022-02438-6 · Cited by 232
“AMPK activation (phosphorylation of α subunit at thr172) is suggested to alleviate inflammation and promote microglial/macrophage polarization to the M2-phenotype [30, 31].”
BackgroundNguyen, H. M., Grössinger, E. M., Horiuchi, M., Davis, K. W., Jin, L., Maezawa, I., & Wulff, H. (2017) · Glia · doi:10.1002/glia.23078 · Cited by 178
“Resting, or more appropriately termed “surveillant” microglia continuously survey their environment with fine cellular processes (Nimmerjahn et al., 2005).”
BackgroundMethodFunctional Role of Regulatory Lymphocytes in Stroke
Liesz, A., Hu, X., Kleinschnitz, C., & Offner, H. (2015) · Stroke · doi:10.1161/strokeaha.114.008608 · Cited by 186
Lü, Y., Li, C., Chen, Q., Liu, P., Guo, Q., Zhang, Y., Chen, X., Zhang, Y., Zhou, W., Liang, D., et al. (2019) · Advanced Materials · doi:10.1002/adma.201808361 · Cited by 185
Paradoxical changes in innate immunity in aging: recent progress and new directions
Montgomery, R. R., & Shaw, A. C. (2015) · Journal of Leukocyte Biology · doi:10.1189/jlb.5mr0315-104r · Cited by 147
“[40] and age-associated cardiac dysfunction [41].”
Inflammatory aspects of epileptogenesis: contribution of molecular inflammatory mechanisms
Alyu, F., & Dikmen, M. (2016) · Acta Neuropsychiatrica · doi:10.1017/neu.2016.47 · Cited by 163
“In addition, reduction of microglia-mediated neuroinflammation has been suggested to involve mTOR pathway (100).”
BackgroundLi, D., Wang, C.-J., Yao, Y., Chen, L., Liu, G., Zhang, R., Liu, Q., Shi, F.-D., & Hao, J. (2016) · The FASEB Journal · doi:10.1096/fj.201600495r · Cited by 147
The potential role of necroptosis in inflammaging and aging
Royce, G. H., Brown‐Borg, H. M., & Deepa, S. S. (2019) · GeroScience · doi:10.1007/s11357-019-00131-w · Cited by 137
Shekhar, S., Cunningham, M., Pabbidi, M. R., Wang, S., Booz, G. W., & Fan, F. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.06.028 · Cited by 130
“• Mammalian target of rapamycin (mTOR) pathway is a known regulator of immune responses, and inhibition of the mTORC1 pathway pharmacologically or genetically prevents microglial polarization toward the M1 pro-inflammatory phenotype in the context of ischemic stroke (Li et al., 2016; Xie et al., 2014).”
Goldshmit, Y., Kanner, S., Zacs, M., Frisca, F., Pinto, A. R., Currie, P. D., & Pinkas‐Kramarski, R. (2015) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2015.04.006 · Cited by 122
Peripheral immune cells infiltrate into sites of secondary neurodegeneration after ischemic stroke
Jones, K., Maltby, S., Plank, M. W., Kluge, M. G., Nilsson, M., Foster, P. S., & Walker, F. R. (2017) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2017.09.006 · Cited by 131
Dynamics of T cell responses after stroke.
Gill, D., & Veltkamp, R. (2016) · Current opinion in pharmacology (Print) · doi:10.1016/j.coph.2015.09.009 · Cited by 116
“Indeed, the therapeutic benefit of harnessing Treg mediated protection has been explored with rapamycin, an inhibitor of mammalian target of rapamycin (mTOR) signalling [34].”
BackgroundA New Model of Cuprizone-Mediated Demyelination/Remyelination
Sachs, H. H., Bercury, K. K., Popescu, D. C., Narayanan, S. P., & Macklin, W. B. (2014) · ASN NEURO · doi:10.1177/1759091414551955 · Cited by 128
Na, S., Mracsko, E., Liesz, A., Hünig, T., & Veltkamp, R. (2015) · Stroke · doi:10.1161/strokeaha.114.007756 · Cited by 108
“Compared with direct adoptive Treg cell transfer, which is technically demanding and time consuming,(10,11) pharmacological amplification of endogenous Treg may be more feasible in acute stroke.(11,12) The superagonistic CD28 monoclonal antibody (CD28SA) activates T cells without T cell receptor engagement.”
BackgroundResultKrämer, T. J., Hack, N., Brühl, T. J., Menzel, L., Hummel, R., Griemert, E., Klein, M., Thal, S., Bopp, T., & Schäfer, M. K. E. (2019) · Journal of Neuroinflammation · doi:10.1186/s12974-019-1550-0 · Cited by 99
Anti-inflammatory treatments for stroke: from bench to bedside
Drieu, A., Levard, D., Vivien, D., & Rubio, M. (2018) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756286418789854 · Cited by 101
Experimental ischemic stroke induces long-term T cell activation in the brain
Xie, L., Li, W., Hersh, J., Liu, R., & Yang, S. (2018) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x18792372 · Cited by 95
“Isolation of immune cells from the brains and spleens was performed at day 3 or one month post-MCAO as published earlier.(27,29) Briefly, mouse cerebral hemispheres and spleens were cut into 1 mm(3) pieces before digestion for 45min at 37 C with digestion buffer (RPMI 1640 medium supplemented with 10% fetal bovine ser…”
MethodSelf-citationYe, J., Jiang, Z., Chen, X., Liu, M., Li, J., & Liu, N. (2017) · Journal of Neurochemistry · doi:10.1111/jnc.14042 · Cited by 96
“Also, rapamycin has been found as a direct inducer of M1 polarization of macrophages and microglia, it also strongly enhances Treg activity, which in turn restrains the inflammatory response of macrophages and microglia (Xie et al. 2014).”
BackgroundBeccari, S., Sierra-Torre, V., Valero, J., Pereira-Iglesias, M., García-Zaballa, M., Soria, F. N., De Las Heras-Garcia, L., Carretero-Guillen, A., Capetillo-Zarate, E., Domercq, M., et al. (2023) · Autophagy · doi:10.1080/15548627.2023.2165313 · Cited by 89
“systemic administration of rapamycin may modulate peripheral immune cell inflammatory profile and activities, including their migration to the CNS, indirectly affecting microglial functions [66].”
BackgroundRegulatory T Cells in Post-stroke Immune Homeostasis
Liesz, A., & Kleinschnitz, C. (2016) · Translational Stroke Research · doi:10.1007/s12975-016-0465-7 · Cited by 97
“exacerbation of stroke outcome after Treg depletion also observed an associated increase in neuroinflammatory biomarkers [17, 21, 38].”
InfluentialGabandé‐Rodríguez, E., Heras, M. M. G. D. L., & Mittelbrunn, M. (2019) · Cells · doi:10.3390/cells9010082 · Cited by 101
Yang, J., Ding, S., Huang, W., Hu, J., Huang, S., Zhang, Y., & Zhuge, Q. (2016) · Frontiers in Neuroscience · doi:10.3389/fnins.2016.00061 · Cited by 88
“For M1 makers, we found that the expression level of iNOS (P < 0.01; n = 6) was significantly increased at 1 day post ICH (Figure 1A), while those of IL-1β (P < 0.05; n = 6), TNF-α (P < 0.05; n = 6), and IL-6 (P < 0.01; n = 6) were increased at 3 h post ICH (Figures 1B–”
BackgroundInfluentialCai, W., Liu, S., Hu, M., Sun, X., Qiu, W., Zheng, S., Hu, X., & Lu, Z. (2018) · Translational Stroke Research · doi:10.1007/s12975-018-0662-7 · Cited by 87
Duan, M., Xu, Y., Li, Y., Feng, H., & Chen, Y. (2024) · Journal of Neuroinflammation · doi:10.1186/s12974-024-03101-y · Cited by 85
“In terms of neuroprotective effects, researchers have demonstrated in stroke models that the mTOR inhibitor rapamycin protects neurons through the anti-inflammatory effects of Tregs [295, 296].”
BackgroundRapamycin prevents cerebral stroke by modulating apoptosis and autophagy in penumbra in rats
Wu, M.-L., Zhang, H.-D., Kai, J.-J., Zhu, F., Dong, J.-Y., Xu, Z.-W., Wong, M., & Zeng, L.-H. (2017) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.507 · Cited by 73
“Currently, systemic thrombolysis with recombinant intravenous tissue plasminogen activator (rtPA) remains a frequently used therapy which can improve clinical outcome of patients with acute ischemic stroke.(3,4) However, rtPA has an increased risk of hemorrhage beyond a few hours of poststroke, and only less than 4% o…”
BackgroundShi, X.-D., Xu, L., Doycheva, D., Tang, J.-P., Yan, M., & Zhang, J. H. (2017) · Journal of Cerebral Blood Flow and Metabolism · doi:10.1177/0271678x16656201 · Cited by 72
He, T., Li, W., Song, Y., Li, Z., Tang, Y., Zhang, Z., & Yang, G. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-020-01987-y · Cited by 80
“It has been shown that blockade of mTORC1 signaling enabled microglia to polarize toward the M2 phenotype to exert anti-inflammatory effects after stroke [47, 48].”
BackgroundKrystal, J. H., Kaye, A. P., Jefferson, S., Girgenti, M. J., Wilkinson, S. T., Sanacora, G., & Esterlis, I. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2305772120 · Cited by 83
Lastra, G., & Manrique, C. M. (2015) · Hormone Molecular Biology and Clinical Investigation · doi:10.1515/hmbci-2015-0010 · Cited by 70
“Loss of Tregs function has been shown to result in M1 macrophage polarization and inflammation [51, 52].”
BackgroundThe Role of Gamma-Delta T Cells in Diseases of the Central Nervous System
Wo, J., Zhang, F., Li, Z., Sun, C., Zhang, W.-C., & Sun, G. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.580304 · Cited by 81
“Hence, gd T cells and IL-17 should be considered potential therapeutic targets to decrease secondary inflammation after ischemic brain injury (105, 106).”
BackgroundHost Resistance and Immune Aging
Bandaranayake, T., & Shaw, A. C. (2016) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2016.02.007 · Cited by 88
Rezabakhsh, A., Ahmadi, M., Khaksar, M., Montaseri, A., Malekinejad, H., Rahbarghazi, R., & Garjani, A. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.07.044 · Cited by 67
Positive effects of intermittent fasting in ischemic stroke
Fann, D. Y., Ng, G. Y. Q., Poh, L., & Arumugam, T. V. (2017) · Experimental Gerontology · doi:10.1016/j.exger.2017.01.014 · Cited by 73
“…cell adhesion molecules (E-selectin, ICAM-1 and VCAM-1) in rodent brains following cerebral ischemia (Aljada et al., 2006; Harari and Liao, 2010; Howard et al., 1998; Lee et al., 2015; Nam et al., 2009; Sanacora et al., 2014; Supanc et al., n.d.; Xing and Remick, 2007; Zampetaki et al., 2004).”
The Effect of A 2A Receptor Antagonist on Microglial Activation in Experimental Glaucoma
Liu, X., Huang, P. C., Wang, J., Yang, Z., Huang, S., Luo, X., Qi, J., Shen, X. P., & Zhong, Y. (2016) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.15-18024 · Cited by 52
Self-citationCD8 signaling in microglia/macrophage M1 polarization in a rat model of cerebral ischemia
Boddaert, J., Bielen, K., ’s Jongers, B., Manocha, E., Yperzeele, L., Cras, P., Pirici, D., & Kumar-Singh, S. (2018) · PLOS ONE · doi:10.1371/journal.pone.0186937 · Cited by 54
Rapamycin in ischemic stroke: Old drug, new tricks?
Hadley, G., Beard, D. J., Couch, Y., Neuhaus, A. A., Adriaanse, B. A., DeLuca, G. C., Sutherland, B. A., & Buchan, A. M. (2018) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x18807309 · Cited by 62
Role of mTOR inhibitors in epilepsy treatment
Sadowski, K., Kotulska, K., & Jóźwiak, S. (2015) · Pharmacological Reports · doi:10.1016/j.pharep.2014.12.017 · Cited by 51
Impact of aging immune system on neurodegeneration and potential immunotherapies
Liang, Z., Zhao, Y., Ruan, L., Zhu, L., Jin, K., Zhuge, Q., Su, D., & Zhao, Y. L. (2017) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2017.07.006 · Cited by 64
Self-citationEverolimus is better than rapamycin in attenuating neuroinflammation in kainic acid-induced seizures
Yang, M., Lin, Y., Ho, W.-H., Liu, C., & Lee, W. (2017) · Journal of Neuroinflammation · doi:10.1186/s12974-017-0797-6 · Cited by 54
“Rapamycin (or sirolimus), the prototype mTOR inhibitor, enhanced the anti-inflammatory activities of regulatory T cells, decreased the production of proinflammatory cytokines and chemokines by macrophages and microglia, and thus attenuated secondary injury after focal ischemia in rats [18].”
BackgroundZimmer, T. S., Broekaart, D. W. M., Gruber, V.-E., van Vliet, E. A., Mühlebner, A., & Aronica, E. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.01028 · Cited by 48
“Treatment with rapamycin or its derivatives everolimus or sirolimus could revert medial cerebral artery occlusion (MCAO)–induced increases of cytokines and/or chemokines, as well as promote anti-inflammatory microglial polarization (222, 223).”
Treg cell: Critical role of regulatory T-cells in depression
Gao, X. W., Tang, Y., Kong, L., Fan, Y., Wang, C., & Wang, R. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106893 · Cited by 51
Soltani, A., Bahreyni, A., Boroumand, N., Roshan, M. K., Khazaei, M., Ryzhikov, M., Soleimanpour, S., Avan, A., & Hassanian, S. M. (2017) · Journal of Cellular Physiology · doi:10.1002/jcp.26276 · Cited by 50
“inhibition of macrophage- and microglia-mediated proinflammatory cytokines and chemokines in ischemic stroke rats (Xie et al., 2014).”
BackgroundInfluentialYou, W.-C., Wang, Z., Li, H., Shen, H.-T., Xu, X., Jia, G., & Chen, G. (2016) · Journal of Neurological Sciences · doi:10.1016/j.jns.2016.06.021 · Cited by 48
mTOR pathway: A potential therapeutic target for spinal cord injury
Ding, Y., & Chen, Q. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112430 · Cited by 53
Yu, G., Liang, Y., Zheng, S., & Zhang, H. (2018) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.117.245688 · Cited by 47
“Several studies found that drugs which downregulate M1 macrophage/microglia and/or upregulate M2 macrophage/microglia polarization are beneficial for MCAO mice to recover from ischemic/reperfusion injury (Jin et al., 2014; Xie et al., 2014).”
BackgroundEssential Role of mTORC1 in Self-Renewal of Murine Alveolar Macrophages
Deng, W., Yang, J., Lin, X., Shin, J., Gao, J., & Zhong, X. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1501845 · Cited by 47
mTOR signaling in immune cells and its implications for cancer immunotherapy
Zeng, H. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.08.038 · Cited by 54
Melatonin receptor agonist ramelteon attenuates mouse acute and chronic ischemic brain injury
Wu, X.-L., Lu, S.-S., Liu, M.-R., Tang, W.-D., Chen, J.-Z., Zheng, Y.-R., Ahsan, A., Cao, M., Jiang, L., Hu, W., et al. (2020) · Acta Pharmacologica Sinica · doi:10.1038/s41401-020-0361-2 · Cited by 43
“mTOR signaling was reported to regulate neuroinflammation [33, 34], which is involved in the pathological process of cerebral ischemia [35].”
BackgroundRegulatory T lymphocytes as a therapy for ischemic stroke
Wang, M., Thomson, A., Yu, F., Hazra, R., Junagade, A., & Hu, X.-M. (2022) · Seminars in Immunopathology · doi:10.1007/s00281-022-00975-z · Cited by 40
“Rapamycin Rat Focal ischemic stroke Enhanced anti-inflammatory activity of Tregs; reduced lesion volume; decreased production of pro-inflammatory cytokines by macrophages and microglia [148]”
BackgroundZhang, T., Guo, J., Gu, J., Chen, K., Li, H., & Wang, J. (2019) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2019/7861290 · Cited by 41
Self-citationAutophagy Modulators and Neuroinflammation
Cho, K. S., Lee, J. H., Cho, J., Cha, G., & Song, G. J. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867325666181031144605 · Cited by 49
Yamada, D., Kawabe, K., Tosa, I., Tsukamoto, S., Nakazato, R., Kou, M., Fujikawa, K., Nakamura, S., Ono, M., Oohashi, T., et al. (2019) · Communications Biology · doi:10.1038/s42003-019-0582-4 · Cited by 41
Shu, L., Xu, C.-Q., Yan, Z.-Y., Yan, Y., Jiang, S.-Z., & Wang, Y.-R. (2019) · Inflammation · doi:10.1007/s10753-019-01057-3 · Cited by 44
“also demonstrate that enhancing the anti-inflammation activity of Tregs can attenuate secondary injury and motor deficits after focal ischemia by to restrain poststroke neuroinflammation [29, 30].”
BackgroundFilho, C. D. D. M., Kappeler, L., Dupont, J., Solinc, J., Villapol, S., Denis, C., Nosten‐Bertrand, M., Billard, J., Blaise, A., Tronche, F., et al. (2016) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x15626718 · Cited by 46
Kong, T., Park, J.-M., Jang, J., Kim, C.-Y., Bae, S.-H., Choi, Y., Jeong, Y.-H., Kim, C., Chang, S.-W.-O., Kim, J., et al. (2018) · Experimental and Molecular Medicine · doi:10.1038/emm.2017.233 · Cited by 37
E-selectin targeted immunoliposomes for rapamycin delivery to activated endothelial cells
Gholizadeh, S., Visweswaran, G. R. R., Storm, G., Hennink, W. E., Kamps, J. A. A. M., & Kok, R. J. (2017) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2017.10.027 · Cited by 38
“Recent studies have highlighted the pivotal role of the mTOR pathways in inflammatory disorders (Cejka et al., 2010; Xie et al., 2014; Weichhart et al., 2015; Li et al., 2016).”
BackgroundInhibition of the Akt1-mTORC1 Axis Alters Venous Remodeling to Improve Arteriovenous Fistula Patency
Guo, X.-J., Fereydooni, A., Isaji, T., Gorecka, J., Liu, S., Hu, H., Ono, S., Alozie, M., Lee, S.-R., Taniguchi, R., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-47542-5 · Cited by 35
Han, R., Gao, J., Zhai, H., Xiao, J., Ding, Y., & Hao, J. (2016) · Experimental Neurology · doi:10.1016/j.expneurol.2016.04.005 · Cited by 37
Beard, D. J., Hadley, G., Thurley, N., Howells, D., Sutherland, B. A., & Buchan, A. (2018) · International Journal of Stroke · doi:10.1177/1747493018816503 · Cited by 34
Wang, P., He, Y., Li, D., Han, R.-R., Liu, G., Kong, D., & Hao, J. (2016) · Journal of Neuroinflammation · doi:10.1186/s12974-016-0660-1 · Cited by 34
“The inhibition of mTORC1 is also believed to prevent the microglial/macrophage phenotype toward to a detrimental state, significantly enhancing beneficial anti-inflammatory activity and decreasing the production of pro-inflammatory cytokines and chemokines [33].”
BackgroundFriend or foe: the dichotomous impact of T cells on neuro-de/re-generation during aging
Coder, B., Wang, W., Wang, L., Wu, Z., Zhuge, Q., & Su, D. (2016) · Oncotarget · doi:10.18632/oncotarget.12572 · Cited by 36
Self-citationLin, W.-P., Chen, W., Liu, W.-F., Xu, Z., & Zhang, L.-Q. (2019) · Immunology · doi:10.1111/imm.13123 · Cited by 32
Dai, K., Huang, L., Sun, X., Yang, L., & Gong, Z. (2015) · Journal of Leukocyte Biology · doi:10.1189/jlb.4a0415-152r · Cited by 32
“[22].”
The role of hypernitrosylation in the pathogenesis and pathophysiology of neuroprogressive diseases
Morris, G., Walder, K. R., Carvalho, A. F., Tye, S. J., Lucas, K., Berk, M., & Maes, M. H. J. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2017.07.017 · Cited by 33
Senousy, M. A., Hanafy, M. E., Shehata, N., & Rizk, S. M. (2022) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.1c00523 · Cited by 33
Sahan-Firat, S., Temiz-Resitoglu, M., Guden, D., Kucukkavruk, S. P., Tunçtan, B., Sari, A. N., Kocak, Z., & Malik, K. (2017) · Inflammation · doi:10.1007/s10753-017-0686-2 · Cited by 30
Yang, H.-N., Zhang, A., Zhang, Y., Ma, S., & Wang, C.-L. (2016) · Journal of Stroke & Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2016.04.014 · Cited by 30
Yuan, H., Wu, G., Zhai, X., Lu, B., Meng, B., & Chen, J. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00314 · Cited by 33
Chi, O., Barsoum, S., Vega-Cotto, N. M., Jacinto, E., Liu, X., Mellender, S., & Weiss, H. R. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2015.12.045 · Cited by 29
“However, other investigators have suggested that treatment with rapamycin, and therefore inhibition of mTOR, is neuroprotective (Guo et al., 2014; Qi et al., 2014; Xie et al., 2014).”
BackgroundDuan, Z., Su, Z., Wang, H.-S., & Pang, X. (2018) · Molecular Pain · doi:10.1177/1744806918769426 · Cited by 28
“Rapamycin, the prototype of selective mTOR inhibitor, enhances the anti-inflammatory activities of regulatory T cells and decreases the production of PICs and chemokines by macrophages in addition to other immune cells.(23) Recent studies have suggested the role of mTOR in regulating a number of inflammatory and autoi…”
BackgroundT-cell receptor signaling modulated by the co-receptors: Potential targets for stroke treatment
Liu, Y., Chen, S., Liu, S., Wallace, K. L., Zille, M., Zhang, J., Wang, J., & Jiang, C. Q. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106797 · Cited by 31
Self-citationBeneficial Effects of Resveratrol-Mediated Inhibition of the mTOR Pathway in Spinal Cord Injury
Zhou, J., Huo, X., Botchway, B. O. A., Xu, L. K., Meng, X., Zhang, S., & Liu, X. (2018) · Neural Plasticity · doi:10.1155/2018/7513748 · Cited by 30
Emerging Targets for Modulation of Immune Response and Inflammation in Stroke
Thapa, K., Shivam, K., Khan, H., Kaur, A., Dua, K., Singh, S. K., & Singh, T. G. (2023) · Neurochemical Research · doi:10.1007/s11064-023-03875-2 · Cited by 29
“CD28SA, an anti-CD28 antibody, has been shown to boost Treg cell numbers and proliferation [254, 256].”
BackgroundFDA-Approved Kinase Inhibitors in Preclinical and Clinical Trials for Neurological Disorders
Lui, A., Vanleuven, J., Perekopskiy, D., Liu, D., Xu, D., Alzayat, O., Elgokhy, T., Do, T., Gann, M., Martin, R. M., et al. (2022) · Pharmaceuticals · doi:10.3390/ph15121546 · Cited by 36
Rezabakhsh, A., Montazersaheb, S., Nabat, E., Hassanpour, M., Montaseri, A., Malekinejad, H., Movassaghpour, A. A., Rahbarghazi, R., & Garjani, A. (2017) · Bioimpacts · doi:10.15171/bi.2017.26 · Cited by 29
Song, M.-A., Ahn, J., Kim, H., Kim, D. W., Lee, T.-K., Lee, J.-C., Kim, Y.-M., Lee, C.-H., Hwang, I., Yan, B., et al. (2018) · Neurochemistry International · doi:10.1016/j.neuint.2018.09.009 · Cited by 23
“It has been reported that treatment with rapamycin reduces infarct volume via inhibiting microglia-mediated proinflammatory activity after transient focal cerebral ischemia in rats (Xie et al., 2014).”
mTOR inhibition potentiates cytotoxicity of Vγ4 γδ T cells via up-regulating NKG2D and TNF-α
Cao, G., Wang, Q., Li, G., Meng, Z., Liu, H., Tong, J., Huang, W., Liu, Z., Jia, Y., Wei, J., et al. (2016) · Journal of Leukocyte Biology · doi:10.1189/jlb.5a0116-053rr · Cited by 33
Immunohistochemical Assessment of Phosphorylated mTORC1-Pathway Proteins in Human Brain Tumors
Harter, P. N., Jennewein, L., Baumgarten, P., Ilina, E. I., Burger, M. C., Thiepold, A., Tichy, J., Zörnig, M., Senft, C., Steinbach, J., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0127123 · Cited by 23
“mTOR-activity has been described not only in the context of oncogenic signaling but has also been observed in reactive brain tissue especially in astrocytes and microglia after traumatic brain injuries [31] and stroke [32], while in case of glioma-activated microglia mTOR-inhibition polarized microglia to a M1-phenoty…”
BackgroundThe role of Wnt/mTOR signaling in spinal cord injury
Peng, C. M., Liao, H.-Y., & Zhang, H. (2022) · Journal of Clinical Orthopaedics and Trauma · doi:10.1016/j.jcot.2022.101760 · Cited by 24
The effect of fingolimod on regulatory T cells in a mouse model of brain ischaemia
Malone, K., Díaz, A. D., Shearer, J. A., Moore, A., & Waeber, C. (2021) · Journal of Neuroinflammation · doi:10.1186/s12974-021-02083-5 · Cited by 24
Diverse functions and mechanisms of regulatory T cell in ischemic stroke
Wu, Y., Li, J., Shou, J., Zhang, W., & Chen, C. (2021) · Experimental Neurology · doi:10.1016/j.expneurol.2021.113782 · Cited by 26
Adenosine Receptors in Modulation of Central Nervous System Disorders
Choudhury, H., Chellappan, D. K., Sengupta, P., Pandey, M., & Gorain, B. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666190712181955 · Cited by 27
Mammalian Target of Rapamycin at the Crossroad Between Alzheimer’s Disease and Diabetes
Liang, H., Nie, J., Skike, C. E. V., Valentine, J. M., & Orr, M. E. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-981-13-3540-2_10 · Cited by 24
van Rees, G. F., Lago, S. G., Cox, D., Tomasik, J., Rustogi, N., Weigelt, K., Özcan, S., Cooper, J. D., Drexhage, H. A., Leweke, F. M., et al. (2017) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2017.10.003 · Cited by 22
Li, X., Gu, S., Ling, Y., Shen, C., Cao, X., & Xie, R. (2015) · Brain Research · doi:10.1016/j.brainres.2015.02.009 · Cited by 23
Bojja, S. L., Medhi, B., Anand, S., Bhatia, A., Joshi, R., & Minz, R. W. (2021) · Inflammopharmacology · doi:10.1007/s10787-020-00782-8 · Cited by 24
Regulatory T cells in ischemic stroke
Wang, H.-Y., Ye, J.-R., Cui, L.-Y., Chu, S.-F., & Chen, N.-H. (2021) · Acta Pharmacologica Sinica · doi:10.1038/s41401-021-00641-4 · Cited by 17
Regulatory T Cells for Stroke Recovery: A Promising Immune Therapeutic Strategy
Li, N., Wang, H., Hu, C., Qie, S., & Liu, Z. (2025) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.70248 · Cited by 19
“Combining recombinant IL-2 with the mTOR inhibitor rapamycin and anti-CD3/CD28 beads can achieve selective Treg proliferation by suppressing the proliferation of non-Treg T-cell subsets [98, 99].”
He, X., Lin, S., Lidan, Y., Tan, P., Ma, P., Qiu, P., Zheng, C., Zhang, X., Kang, W., & Lin, W. (2021) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2021.577546 · Cited by 20
Oku, H., Morishita, S., Horie, T., Kida, T., Mimura, M., Kojima, S., & Ikeda, T. (2017) · Investigative Ophthalmology and Visual Science · doi:10.1167/iovs.17-22179 · Cited by 17
Kagitani‐Shimono, K., Kato, H., Soeda, F., Iwatani, Y., Mukai, M., Ogawa, K., Tominaga, K., Nabatame, S., & Taniike, M. (2022) · NeuroImage Clinical · doi:10.1016/j.nicl.2022.103288 · Cited by 17
Zhang, X.-L., Jiang, N., Li, J., Zhang, D.-Y., & Lv, X. (2018) · Neurological Research · doi:10.1080/01616412.2018.1531199 · Cited by 16
“selective mTOR inhibitor, enhances the anti-inflammatory activities of regulatory T cells and decreases the production of PICs and chemokines by macrophages in addition to other immune cells [24].”
BackgroundJiang, R.-H., Xu, X.-Q., Wu, C.-J., Lu, S.-S., Zu, Q., Zhao, L.-B., Liu, S., & Shi, H.-B. (2018) · Neurological Research · doi:10.1080/01616412.2018.1473075 · Cited by 16
“pathway plays an important part in ischemic stroke, and the inhibition of mTORC1 signaling may be a protective mechanism [14].”
Background
Metadata
- Authors
- Xie, L., Sun, F., Wang, J., Mao, X., Xie, L., Yang, S.-H., Su, D.-M., Simpkins, J. W., Greenberg, D. A., & Jin, K.
- Affiliations
- Buck Institute for Research on Aging (US)
- University of North Texas Health Science Center (US)
- West Virginia University (US)
- Department of Pharmacology and Neuroscience, Institute for Aging and Alzheimer’s Disease Research, University of North Texas Health Science Center , Fort Worth, TX 76107
- Corresponding author
- Xie, Luokun
- Sun, Fen
- Wang, Jixian
- ORCID
- Sun, Fen
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2014-06
- Volume
- 192
- Issue
- 12
- Pages
- 6009-6019
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- PMC
- PMC4128178
- OpenAlex
- W1618035875
- Cited by
- 175
- References
- 76
- Citations by year
- 2026: 4 · 2025: 9 · 2024: 6 · 2023: 19 · 2022: 11 · 2021: 26 · 2020: 12 · 2019: 19 · 2018: 15 · 2017: 18 · 2016: 21 · 2015: 12 · 2014: 2
- FWCI
- 9.20
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The Journal of Immunology (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- The Research Repository @ WVU (West Virginia University) (submittedVersion)
- Funders
- University of North Texas
- National Institute on Aging (R01AG021980, AG21980, P01AG027956)
- National Institute of General Medical Sciences (U54GM104942)
- National Institute of Neurological Disorders and Stroke (NS57186, NS054651, NS054687, R01NS054687, R01NS057186, R01NS054651)
- Topics
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Health Sciences › Medicine › Clinical Neurology › Acute Ischemic Stroke Management
- Health Sciences › Medicine › Clinical Neurology › Traumatic Brain Injury and Neurovascular Disturbances
- Keywords
- mTOR signaling, rapamycin, focal ischemic stroke, regulatory T cells, macrophage polarization, microglia, γδ T cells, granulocytes, inflammatory cytokines, chemokines, secondary brain injury, motor impairment, intracerebroventricular administration
- MeSH terms
- Animals, Brain Ischemia, Immunosuppressive Agents, Inflammation, Macrophages, Male, Signal Transduction, Receptors, Antigen, T-Cell, gamma-delta, Rats, Sprague-Dawley, Microglia, Sirolimus, Stroke, T-Lymphocytes, Regulatory, Rats, TOR Serine-Threonine Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
